Icosapent Ethyl - ASCVD & Lipidology Knowledge Hub

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm
  • Share

  • Stay up to date
  • Home
  • Topics
    • Cardiovascular Diseases and Conditions
      • Acute Coronary Syndrome
      • ASCVD
      • Atherosclerosis
      • Coronary artery disease
      • CVD
      • ASCVD
      • Myocardial Infarction
    • Lipid Metabolism and Disorders
      • Lipids
        • PUFA
          • Eicosanoids
      • Cholesterol
        • High-density lipoprotein
        • Low-density lipoprotein
        • Low-density Lipoprotein Cholesterol
        • Lipoprotein (a)
        • Apolipoprotein B
        • Hypercholesterolemia
        • Hyperlipidemia
        • Dyslipidemia
        • Familial hypercholesterolemia
      • Triglycerides
      • Cholesterol synthesis
      • Cholesterol absorption
    • Medications and Therapies
      • Therapy
      • Lipid lowering therapy
        • Statin
          • High-intensity statin
        • PCSK9
          • Alirocumab
          • Evolocumab
        • Bempedoic acid
        • Icosapent Ethyl
        • Inclisiran
        • Obicetrapib
        • Zerlasiran
      • Combination therapy
      • Aspirin
      • Immunotherapy
      • Short interfering RNA (siRNA)
      • Diabetes
    • Risk Factors and Prevention
      • CVD Risk Factor
      • Primary prevention
      • Prevention
      • Risk assessment
      • Women
      • Inflammation
      • Calcium Scoring
      • Models
    • Clinical Research and Guidelines
      • Clinical Trial
      • Trials
      • Guidelines
      • Consensus statement
      • Registry
      • GOULD
      • Long-term studies
      • Case Studies
    • Other Related Topics
      • Congresses
      • Global health
      • Vaccination
        • Influenza
      • Non-adherence
      • Pediatric Population
      • Plaques
      • Obesity
    • Molecular and Genetic Factors
      • ANGPTL3
      • Pharmacogenomics
  • Webinars/Videos
  • Infographics
  • Articles
  • Case Studies
  • Forum
  • Faculty
  • Unblocked
  • Stay up to date

Icosapent Ethyl

Video Library

  • Running time: 9 minutes 45 seconds

    Video Library

    Role of Eicosanoids in Atherosclerosis, with a Focus on Icosapent Ethyl (IPE) as a Therapeutic Option for Cardiovascular Disease

    In this video, Prof. Deepak L. Bhatt presents an infographic on the role of eicosanoids in atherosclerosis with a focus on IPE as therapeutic option for CVD.

    View
    • Share

Infographics

  • Infographics

    Understanding the Role of Eicosanoids in Atherosclerosis, with a Focus on Icosapent Ethyl as a Therapeutic Option for Cardiovascular Disease

    Eicosanoids are lipid-based mediators which play crucial roles in the inflammatory response and the development of ASCVD. This infographic delves into the intricate involvement of eicosanoids in atherosclerosis and highlights how icosapent ethyl serves as a key therapeutic option to mitigate ASCVD risks.

    View
    • Share

Articles

  • Articles

    Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

    View
    • Share

  • Articles

    Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl

    View
    • Share

How would you rate this content?

  • © John Wiley & Sons, Ltd. All rights reserved.
  • Privacy Policy
  • Terms of use
  • Stay up to date
  • Cookie Preferences
  • This Knowledge Hub is supported by Novartis.
Clinical Cardiology